Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are: * Does the investigational therapy lead to regression of cervical lesions? * Does the investigational therapy help clear hr-HPV infection? * Do any adverse effects occur from using this medical product? Researchers will compare the investig

Trial Details

NCT ID
NCT07572396
Phase
PHASE2
Sponsor
Amplexd Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • EGCG and Quinine Sulfate Vaginal Suppository
  • Placebo
Locations (sample)
  • Shatin, New Territories, Hong Kong|22.38333,114.18333

Key Eligibility Criteria

  • Participants must meet all the following criteria to be eligible to enroll in the study:
  • Participants capable of giving informed consent
  • Females, ages 18 to 65 years old at the time of signature of the informed consent form.
  • Participants who are able to correctly self-administer the intravaginal suppositories

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →